Jens W Fischer Selected Research

Small Leucine-Rich Proteoglycans

11/2021	The Proteoglycan Biglycan Modulates Platelet Adhesion and Thrombus Formation in a GPVI-Dependent Manner.
1/2019	Degenerative aortic valve disease and diabetes: Implications for a link between proteoglycans and diabetic disorders in the aortic valve.
1/2016	Loss of Biglycan Enhances Thrombin Generation in Apolipoprotein E-Deficient Mice: Implications for Inflammation and Atherosclerosis.
1/2013	Inhibitory role of the small leucine-rich proteoglycan biglycan in bladder cancer.
1/2010	Transcriptional and posttranscriptional regulators of biglycan in cardiac fibroblasts.
1/2010	Long-term treatment with the AT1-receptor antagonist telmisartan inhibits biglycan accumulation in murine atherosclerosis.
12/2004	Decorin promotes aortic smooth muscle cell calcification and colocalizes to calcified regions in human atherosclerotic lesions.
12/2003	Angiotensin II AT(1)-receptor induces biglycan in neonatal cardiac fibroblasts via autocrine release of TGFbeta in vitro.
9/2002	Smad4/DPC4-dependent regulation of biglycan gene expression by transforming growth factor-beta in pancreatic tumor cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jens W Fischer Research Topics

Disease

19	Atherosclerosis 11/2021 - 07/2004
14	Inflammation (Inflammations) 01/2021 - 11/2010
11	Neoplasms (Cancer) 10/2021 - 09/2002
11	Myocardial Infarction 01/2021 - 12/2003
8	Infarction (Infarctions) 01/2021 - 01/2006
8	Atherosclerotic Plaque (Atheroma) 01/2019 - 11/2004
7	Ischemia 10/2021 - 01/2011
6	Thrombosis (Thrombus) 11/2021 - 01/2005
5	Cicatrix (Scar) 01/2021 - 01/2010
5	Neointima 01/2018 - 03/2002
4	Obesity 01/2021 - 01/2019
4	Myocardial Ischemia (Ischemic Heart Diseases) 01/2018 - 07/2008
4	Hyperplasia 02/2016 - 07/2004
3	Hyperglycemia 12/2019 - 11/2014
3	Esophageal Squamous Cell Carcinoma 02/2016 - 07/2010
3	Cardiovascular Diseases (Cardiovascular Disease) 09/2015 - 09/2009
3	Urinary Bladder Neoplasms (Bladder Cancer) 01/2013 - 09/2012
3	Vascular System Injuries 12/2008 - 03/2002
2	Body Weight (Weight, Body) 01/2021 - 01/2019
2	Type 2 Diabetes Mellitus (MODY) 01/2021 - 01/2019
2	Insulin Resistance 12/2019 - 01/2017
2	Diabetes Mellitus 12/2019 - 11/2014
2	Reperfusion Injury 10/2019 - 09/2014
2	Atrial Fibrillation 01/2019 - 09/2016
2	Hypertrophy 01/2019 - 02/2009
2	Fibrosis (Cirrhosis) 01/2017 - 09/2002
2	Ventricular Remodeling 10/2016 - 12/2003
2	Acute Coronary Syndrome 01/2016 - 05/2010
2	Carcinoma (Carcinomatosis) 01/2013 - 09/2012
2	Carotid Stenosis (Carotid Artery Stenosis) 12/2010 - 02/2007
2	Pathologic Constriction (Stenosis) 06/2007 - 07/2004
2	Atrophy 01/2005 - 03/2002
1	Colitis 01/2021
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2021
1	Wilms Tumor (Wilm's Tumor) 01/2021
1	Heart Failure 01/2021
1	Abdominal Obesity 01/2021

Drug/Important Bio-Agent (IBA)

21	Hyaluronic Acid (Hyaluronan)IBA 11/2021 - 01/2005
13	BiglycanIBA 11/2021 - 09/2002
9	Small Leucine-Rich ProteoglycansIBA 11/2021 - 09/2002
9	CollagenIBA 01/2015 - 03/2002
7	Thrombin FDA Link 11/2021 - 04/2007
7	Proteoglycans (Proteoglycan)IBA 11/2021 - 11/2004
7	Apolipoproteins E (ApoE)IBA 01/2018 - 09/2009
6	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 11/2014
6	Messenger RNA (mRNA)IBA 04/2016 - 09/2002
5	ApolipoproteinsIBA 01/2018 - 11/2011
4	IsoenzymesIBA 01/2021 - 01/2013
4	Proteins (Proteins, Gene)FDA Link 01/2021 - 07/2008
4	DecorinIBA 09/2016 - 12/2004
4	ChemokinesIBA 02/2016 - 07/2013
3	Hyaluronan SynthasesIBA 01/2021 - 02/2016
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2018 - 09/2014
3	Collagen Type I (Type I Collagen)IBA 01/2015 - 12/2003
3	Lipoproteins (Lipoprotein)IBA 10/2014 - 11/2004
3	ProstaglandinsIBA 02/2009 - 07/2004
3	Versicans (Versican)IBA 01/2005 - 03/2002
2	Heparin Cofactor IIIBA 11/2021 - 01/2016
2	RNA (Ribonucleic Acid)IBA 01/2021 - 10/2019
2	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 12/2020 - 12/2014
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 12/2020 - 07/2004
2	Biomarkers (Surrogate Marker)IBA 10/2019 - 04/2016
2	Pharmaceutical PreparationsIBA 10/2019 - 01/2019
2	Insulin (Novolin)FDA Link 01/2019 - 01/2017
2	phospholipase D1IBA 01/2018 - 09/2014
2	Adenosine (Adenocard)FDA LinkGeneric 01/2017 - 11/2011
2	Proteinase-Activated ReceptorsIBA 01/2016 - 11/2014
2	CytokinesIBA 01/2016 - 07/2014
2	LigandsIBA 04/2015 - 07/2013
2	Angiotensin IIIBA 10/2014 - 12/2003
2	CarbohydratesIBA 01/2014 - 01/2013
2	Interleukin-6 (Interleukin 6)IBA 01/2014 - 01/2006
2	Estrogens (Estrogen)FDA Link 11/2011 - 12/2009
2	Polysaccharides (Glycans)IBA 03/2011 - 07/2010
2	Thromboplastin (Tissue Factor)IBA 12/2010 - 05/2006
2	Dinoprostone (PGE2)FDA Link 05/2010 - 08/2007
2	OsteopontinIBA 09/2009 - 12/2004
2	TropoelastinIBA 12/2008 - 03/2002
2	GlycosaminoglycansIBA 12/2008 - 11/2004
2	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 08/2007 - 07/2004
2	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 01/2005 - 07/2004
2	Polytetrafluoroethylene (Teflon)FDA Link 01/2005 - 03/2002
1	Recombinant ProteinsIBA 11/2021
1	Sucrose (Saccharose)IBA 01/2021
1	Transcription Factors (Transcription Factor)IBA 01/2021
1	sodium sulfate (sodium bisulfate)FDA LinkGeneric 01/2021
1	Sodium-Glucose Transport ProteinsIBA 01/2021
1	Blood Glucose (Blood Sugar)IBA 01/2021
1	LDL Receptors (LDL Receptor)IBA 01/2021
1	atglistatinIBA 01/2021
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2021
1	HDL CholesterolIBA 01/2021
1	dapagliflozinIBA 01/2021
1	Dextrans (Dextran)FDA Link 01/2021

Therapy/Procedure

6	Therapeutics 01/2021 - 09/2012
4	Ligation 10/2016 - 09/2009
2	Ovariectomy (Oophorectomy) 01/2018 - 06/2012
2	Radiotherapy 01/2017 - 04/2016
2	Catheters 01/2015 - 07/2004
1	Drug Therapy (Chemotherapy) 01/2021